PMID- 33874683 OWN - NLM STAT- MEDLINE DCOM- 20210531 LR - 20210531 IS - 0253-3758 (Print) IS - 0253-3758 (Linking) VI - 49 IP - 4 DP - 2021 Apr 24 TI - [Safety and efficacy of ultrafiltration on heart failure patients with reduced ejection fraction and diuretic resistance: results from a single-center randomized controlled trial]. PG - 340-344 LID - 10.3760/cma.j.cn112148-20200816-00646 [doi] AB - Objective: To investigate the safety and efficacy of ultrafiltration on diuretic sensitivity in heart failure patients with reduced ejection fraction and diuretic resistance. Methods: This was a single-center randomized controlled trial. A total of 148 heart failure patients with reduced ejection fraction admitted to the Hospital of Traditional Chinese Medicine of Xinjiang Uygur Autonomous Region from June 2010 to June 2020 were enrolled in this study, and these patients were randomly divided (ratio 1:1) into the ultrafiltration group (n=74) and the control group (n=74). All patients were treated with diuretics, cardiotonic, vasodilator and other comprehensive drugs according to relevant guidelines. After grouping, the patients in the control group were treated with standard treatment plan, while patients in the ultrafiltration group were treated with ultrafiltration on top of standard therapy. Diuretic drugs were discontinued during ultrafiltration, and intravenously furosemide (40 mg) was given immediately and 24 hours after the end of ultrafiltration. Clinical data including gender, age, complicated diseases, New York Heart Association (NYHA) function classification, etc. were collected. Effectiveness indicators include urine volume (the first 12-hour and 24-hour urine volume and the second 24-hour urine volume after using diuretic), body weight and dyspnea severity score. Safety indicators include systolic blood pressure, serum creatinine, serum Na(+) concentration, blood K(+) concentration and the number of deaths before and after intervention. Results: Two patients in the control group died due to worsening heart failure after randomization and were excluded in this study, 146 patients were finally analyzed (72 patients in the control group and 74 patients in the ultrafiltration group). There were 93 males, and the age was (68.3+/-11.2) years. There was no significant difference between patients in the ultrafiltration group and the control group in gender, age, body weight, course of disease, dyspnea severity score, NYHA function classification Ⅲ/Ⅳ, the proportion of patients with severe edema of both lower limbs, the proportion of patients with complicated diseases, and basic medication (all P>0.05). After using diuretics, the urine volume of the first 12-hour and 24-hour and the second 24-hour were significantly higher in the ultrafiltration group than in the control group (all P<0.05). Body weight decreased significantly after ultrafiltration treatment as compared with that before intervention in the ultrafiltration group (P<0.05). Compared with the control group, the dyspnea severity score was significantly improved in the ultrafiltration group (P<0.05). There was no significant difference in systolic blood pressure, serum creatinine, serum Na(+) concentration, blood K(+) concentration of patients between ultrafiltration group and control group before and after intervention (all P>0.05). During the clinical diagnosis and treatment, 2 male patients in the control group died, and the cause of death was aggravation of basic diseases complicated with acute heart failure and cardiogenic shock. There was no death in the ultrafiltration group, and there were no obvious clinical adverse events during and after ultrafiltration. Conclusion: Ultrafiltration therapy is safe and can improve diuretic sensitivity in heart failure patients with reduced ejection fraction and diuretic resistance. FAU - Shen, X L AU - Shen XL AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Li, L AU - Li L AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Ma, J AU - Ma J AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Zhang, B J AU - Zhang BJ AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Ge, Z R AU - Ge ZR AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Liu, X Z AU - Liu XZ AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Zu, L B Y AU - Zu LBY AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - He, Y AU - He Y AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. FAU - Jiang, S B AU - Jiang SB AD - Heart Center, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, China. LA - chi PT - Journal Article PT - Randomized Controlled Trial PL - China TA - Zhonghua Xin Xue Guan Bing Za Zhi JT - Zhonghua xin xue guan bing za zhi JID - 7910682 RN - 0 (Diuretics) RN - 7LXU5N7ZO5 (Furosemide) SB - IM MH - Aged MH - *Diuretics/therapeutic use MH - Furosemide/therapeutic use MH - *Heart Failure/drug therapy MH - Humans MH - Male MH - Middle Aged MH - Stroke Volume MH - Ultrafiltration EDAT- 2021/04/21 06:00 MHDA- 2021/06/01 06:00 CRDT- 2021/04/20 04:27 PHST- 2021/04/21 06:00 [pubmed] PHST- 2021/06/01 06:00 [medline] PHST- 2021/04/20 04:27 [entrez] AID - 10.3760/cma.j.cn112148-20200816-00646 [doi] PST - ppublish SO - Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Apr 24;49(4):340-344. doi: 10.3760/cma.j.cn112148-20200816-00646.